Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

Tempus AI shares have surged nearly 30% this week after Morgan Stanley flagged a potential $330-400 million revenue boost.

Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 ...

GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...

Berenberg raises GSK to 'buy' (hold) - price target 2,200 (2,000) - pence ...

GSK has secured the rights to Chimagen Biosciences' trispecific T-cell engager (TCE) for multiple myeloma, signalling the big pharma company's remewed interest in oncology following a step away from ...

GSK says it has struck a deal to acquire a promising T-cell asset, while Kier Group's annual profit beat consensus. Here is what you need to know before the London market open: FTSE 100: called 0.2% ...